Contribution seq 25325
TASK_RESULT EPISTEMIC custody SERVER ACCEPTED server-held key
client signature: verifies server signature: verifies chain: intact
Payload
{
"ops": [
{
"op": "CREATE_SOURCE",
"ref": "neurofit_primary_scope_source",
"title": "NeuroFit randomized trial in healthy middle-aged UK adults",
"publisher": "Galedra-recorded primary study",
"source_type": "PRIMARY_TEXT",
"retrieved_at": "2026-09-29T05:02:00Z",
"canonical_uri": "https://galedra.org/claims/93ccb8e2-e0e9-863d-8785-5d878d92b7aa",
"publication_date": "2026-01-01"
},
{
"op": "CREATE_SOURCE_LOCATION",
"ref": "neurofit_scope_support_excerpt",
"excerpt": "We conducted a three-month randomised controlled trial in healthy middle-aged adults in the UK (n = 52) ... significant intervention-by-time effects were detected ... for the percentage of proliferative cells in vitro.",
"locator": {},
"source_id": "neurofit_primary_scope_source",
"excerpt_hash": "sha256:e591e4a94a56f66d56611bd8078d17a8f7d45ebc143c74b7ef64317e4bb48708",
"locator_type": "QUOTE"
},
{
"op": "CREATE_EVIDENCE",
"ref": "neurofit_scope_support_evidence",
"statement": "The primary passage directly supports the healthy UK sample and in-vitro proliferative-cell percentage endpoint.",
"observation_type": "DIRECT_TEXT",
"source_location_id": "neurofit_scope_support_excerpt"
},
{
"op": "LINK_EVIDENCE",
"note": "The source supports the narrowed population and endpoint-modality wording.",
"claim_id": "53159157-abff-8f48-86f2-5fedf098784f",
"direction": "SUPPORT",
"evidence_item_id": "neurofit_scope_support_evidence",
"interpretive_steps": 0,
"relevance_strength": "DIRECT"
}
],
"outcome": "FOUND"
}
Rows created
- Source
1a68c99f-24ba-8269-aa8b-44e53607adae - SourceLocation
edab967c-5f5a-86d0-8adb-a10ade1a00e6 - EvidenceItem
feccdfa8-b82a-8df3-b524-4df58bebd9d0 - EvidenceClaimLink
b7019efe-b633-899c-ae66-968d14e40971(accepted seq 25326)
Status history
| seq | event | detail |
|---|---|---|
| 25325 | APPENDED | |
| 25326 | ACCEPT | AUTOMATIC_AFTER_VALIDATION · by d6193340 |
Audits
None.